President and CEO of VBI Vaccines Set to Present at Jefferies 2017 Global Healthcare Conference

biotech investing, biotech investing news, biotech investments, biotech companies, investing in biotech companies, investing in biotech stocks, biotech invest, biotech investors, new biotech stocks, biotech stocks today, top biotech investors, investing in biotech, biotech sector etf, biotech stock analysis, biotech stocks, invest in biotech, best biotech companies to invest in, biotech stock research, biotech stock market. biotech investment

VBI Vaccines Inc. (NASDAQ:$VBIV), a biopharmaceutical company headquartered in Cambridge, MA, announced today that VBI’s President and CEO, Jeff Baxter, will be presenting at the Jefferies 2017 Global Healthcare Conference on Friday, June 9, 2017 at 12:30 PM ET in New York City.

For those unable to make the conference, there will be a live audio webcast starting at 12:30 ET on http://wsw.com/webcast/jeff105/vbiv

To guarantee timely access, VBI suggests that individuals register for the webcast at least 10 minutes before the presentation starts. Following the event, there will be a replay of the webcast for 90 straight days on the VBI website.

Details of the Conference

A Brief Overview: VBI Vaccines Inc.

As mentioned, VBI Vaccines Inc is a biopharmaceutical company. They specialize in the development of vaccines which are meant to address needs that have not been met in infectious disease and immuno-oncology. VBI’s first product, known as Sci-B-Vac™, has been approved for use in Israel and 14 other countries. Sci-B-Vac™ is a hepatitis B vaccine that has the ability to mimic all three viral surface antigens of the HBV virus. Additionally, VBI has eVLP Platform technology which authorizes the development of enveloped virus-like particle vaccines which mirror the target virus to evoke a potent immune response.

Furthermore, VBI is working on advancing a pipeline of eVLP vaccines and they are advancing their LPV™ Thermostability Platform. This platform is a proprietary process which allows for vaccines and biologics to have stability, potency, and safety.

As previously mentioned, VBI Vaccines is headquartered in Cambridge, MA, but they also have numerous research operations in Ottawa, Canada and manufacturing facilities in Rehovot, Israel.

Featured Image: facebook.com

About the author: Caroline Harris is a third-year student at Capilano University in North Vancouver, Canada. Having already completed an Associates Degree in Psychology, Caroline is now finishing her Bachelor's degree in Communications. In preparation for working in the advertisement sector, Caroline is writing financial content and analysis. On a daily basis, Caroline works on articles regarding the following topics: finance, cryptocurrency, technology, and politics.